BCG033 / Biocytogen - LARVOL DELTA

BCG033: a first-in-class PTK7×TROP2 bispecific ADC demonstrating potent and broad efficacy in various preclinical models (AACR 2025) - "BCG033 backbone antibody demonstrates strong binding activity under varying PTK7 and TROP2 expression levels in tumors, and exhibits promising developability under stress force degradation.In proof of concept studies, BCG033 AB-vcMMAE showed synergistic effect and enhanced activity compared to the parental ADCs in both cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) models of TNBC, even with low PTK7 expression. When conjugated with Biocytogen's linker/payload BLD1102, BCG033 demonstrated superior efficacy across varying PTK7 and TROP2 expression levels in PDX models and consistently outperformed benchmark ADCs in multiple tumor models, including NSCLC, TNBC, gastric cancer, and colorectal cancer.In summary, BCG033 demonstrates promising potential for delivering potent and broad anti-tumor activity across a range of solid tumors, offering broad clinical application opportunities."

Preclinical • Breast Cancer • Colorectal Cancer • Gastric Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2 • PTK7 • TACSTD2

TAA antibody library and novel linker/payload BLD1102 for ADC, bispecific ADC and nanobody-drug conjugate development (SITC 2024) - "Novel ADC and bsADCs, including anti-CH3 ADC (BCG014) and anti-PTK7xTROP2 bsADC (BCG033) were generated using our TAA library and linker/payload system...The library contains RenMice-derived mAbs and HCAbs for over 200 TAAs, many of which have been screened for internalization activity. This ready-to-use resource expedites the large-scale development of ADCs across various modalities.View this table:View inline View popup Download powerpoint Abstract 1049 Table 1 TAA-targeting monoclonal antibody and nanobody libraries available for plug and play"

Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CDH3 • ENTPD1 • PD-L1 • SIRPA • TFRC

TAA antibody library and novel linker/payload BLD1102 for ADC, bispecific ADC and nanobody-drug conjugate development (SITC 2024) - "Novel ADC and bsADCs, including anti-CH3 ADC (BCG014) and anti-PTK7xTROP2 bsADC (BCG033) were generated using our TAA library and linker/payload system...The library contains RenMice-derived mAbs and HCAbs for over 200 TAAs, many of which have been screened for internalization activity. This ready-to-use resource expedites the large-scale development of ADCs across various modalities.View this table:View inline View popup Download powerpoint Abstract 1049 Table 1 TAA-targeting monoclonal antibody and nanobody libraries available for plug and play"

Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CDH3 • ENTPD1 • PD-L1 • SIRPA • TFRC

BCG033, a novel bispecific antibody-drug conjugate targeting PTK7 and TROP2, demonstrates preclinical efficacy against triple-negative breast cancer and other solid tumor xenografts (AACR 2024) - "Although the TROP2-targeting ADC sacituzumab govitecan recently received accelerated approval from the FDA for the treatment of patients with metastatic TNBC, the on-target toxicity of this single-target agent has limited clinical efficacy. We next tested the efficacy of the PTK7 x TROP2 bsAb conjugated to BLD1102, Biocytogen's novel, proprietary linker/payload composed of a DNA Topo I inhibitor payload and a highly hydrophilic protease-cleavable linker, with a DAR of 8. BCG033-BLD1102 showed potent activity in a colorectal cancer PDX model in which benchmark ADCs were inactive, even at high doses.In summary, BCG033 conjugates demonstrate promising preclinical efficacy in vivo, which ultimately could provide a new treatment option for TNBC and other solid tumors expressing PTK7 and TROP2."

Preclinical • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • PTK7 • TACSTD2

World ADC London 2024 | Biocytogen will showcase the latest progress in dual-antibody ADC and plug-and-play TAA antibody libraries [Google translation] (Biocytogen Press Release) - "Biocytogen will participate in the 14th World ADC London Conference on March 13-14, 2024, and give oral reports and poster presentations...Dr. Yang Yi, chief scientist of Biocytogen, will give an oral report...in the Discovery Stream segment on March 13. In the report, Dr. Yang will: Introducing Biocytogen's advanced fully human antibody discovery platform (RenMab , RenLite and RenNano mice), as well as its antibody shelf containing more than 400,000 fully human antibody sequences and characterization data for approximately 1,000 human targets....In addition, Biocytogen’s Antibody Business Development (BDL) team will present 2 posters focusing on the company’s BCG033 (PTK7 x TROP2 dual anti-ADC), as well as the tumor-associated antigen (TAA) antibody library targeting approximately 200 targets and the company’s Proprietary connector/load for ADC assembly."

Clinical • Preclinical • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

A novel bispecific antibody-drug conjugate targeting PTK7 and TROP2, BCG033, demonstrates preclinical efficacy against triple-negative breast cancer xenografts (SITC 2023) - "Although the TROP2-targeting ADC sacituzumab govitecan was recently granted accelerated approval from the FDA for treating patients with metastatic TNBC,1 the on-target toxicity of this single-targeting agent has limited clinical efficacy. Conclusions BCG033 is a novel bispecific antibody-drug conjugate that targets PTK7 and TROP2. BCG033 demonstrates promising preclinical efficacy in vivo, suggesting it may offer new treatment options for TNBC or other solid tumors expressing PTK7 and TROP2 in the future."

Preclinical • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • PTK7 • TACSTD2

Biocytogen Announces 16 Poster Presentations and Booth Exhibition at SITC 2023 (Businesswire) - "Biocytogen Pharmaceuticals (Beijing) Co., Ltd...announced today that the company will be presenting 16 posters and exhibiting at booth 223 at the Society for Immunotherapy of Cancer (SITC) annual conference, taking place from November 1-5, 2023 in San Diego, CA."

Preclinical • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Discovery of BCG033, a novel anti-PTK7 x TROP2 bispecific antibody-drug conjugate with promising efficacy against triple-negative breast cancer (AACR 2023) - "Recently, the TROP2-targeting ADC sacituzumab govitecan has received an accelerated approval from the FDA for adult patients with metastatic TNBC, as more than 85% of TNBC is marked by TROP2 overexpression. Patient-derived TNBC xenografts with co-expression of PTK7 and TROP2 have been screened for future in vivo drug efficacy screening. In summary, BCG033 has the potential to exert anti-tumor efficacy in TNBC and other solid tumors co-expressing PTK7 and TROP2."

Clinical • Late-breaking abstract • Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • PTK7 • TACSTD2 • TROP2